药物诱导的肝损伤中的表观遗传修饰:系统性审查
Romina Lorena de Los Santos-Fernández1, Antonio Segovia-Zafra1,2, Guillermo Paz-López3
1Servicio de Aparato Digestivo y Farmacología clínica, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma BIONAND, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
British journal of clinical pharmacology
|March 26, 2025
概括
表观遗传因素,特别是DNA甲基化,与药物诱导的肺结核药物造成的肝损伤有关. 特定基因促进体和可转移元素的变化可以作为这种疾病的生物标志物.
科学领域:
- 药物基因组学 药物基因组学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 异常药物诱导性肝损伤 (DILI) 是对各种物质的严重不良反应.
- 仅仅遗传因素并不能完全解释DILI的发生,这表明其他调节机制也参与其中.
- 表观遗传特征,如DNA甲基化和长非编码RNA,可以阐明DILI中的遗传调节途径,并作为生物标志物.
研究的目的:
- 系统地审查和分析现有关于药物诱导肝损伤中的表观遗传风险关联的研究.
- 确定特定的表观遗传机制和涉及DILI的基因.
- 评估表观遗传修饰作为DILI生物标志物的潜力.
主要方法:
- 系统的文献审查.
- 包括人口研究分析DILI和表观遗传调节之间的风险关联.
- 专注于研究DILI中的DNA甲基化和长非编码RNA的研究.
主要成果:
- 其中七项研究中有六项研究专注于DNA甲基化,另一个研究长非编码RNA.
- 所有研究都研究了抗结核药物诱导的肝损伤 (ATB-DILI),并来自亚洲.
- 在CYP2D6和NAT2促进体中,CPG位元甲基化显示出ATB-DILI的最高风险.
- 对LINE-1和Alu元素的低甲基化显示出作为ATB-DILI生物标志物的潜力 (AUC 0.94).
结论:
- DNA甲基化修饰是与ATB-DILI相关研究的主要表观遗传变化.
- 这项研究主要来自亚洲,突出了严重的公共卫生问题.
- 表观遗传变化,特别是特定基因和可移植元素的DNA甲基化变化,显示出作为ATB-DILI的诊断和治疗点的希望.
相关概念视频
Epigenetic Regulation
30.8K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
30.8K
Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
Factors Affecting Drug Biotransformation: Biological
90
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
90
Hepatic Drug Excretion: Influencing Factors
70
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
70
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
143
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
143
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
23
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
23


